Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
Hemocompatibility and red blood cell trauma in next-generation total artificial hearts
FY 2025-26
Summary
Heart failure affects more than 750,000 Canadians, with 100,000 new diagnoses each year, costing the health care system $19.5B. For people with severe, end-stage disease, a heart transplant is the best option, but ~15% die while waiting. To fill this gap, mechanical circulatory support devices, such as left ventricular assist devices and total artificial hearts, are used to keep patients alive while waiting for a transplant or as long-term therapy. These devices improve short-term survival but are limited by complications like blood clots, stroke, bleeding and organ failure. Nearly all patients develop clotting problems, causing repeat hospitalizations.
A major reason for these complications is "blood trauma." As blood moves through pumps made of artificial materials, red blood cells (RBCs) are exposed to unnatural stresses and surfaces. Even if RBCs do not burst, they can become stiff, inflamed or break down too quickly, which harms circulation and causes clots, bleeding and poor blood flow. Current safety standards only test for cell rupture (called hemolysis) and miss this subtler damage, leaving a critical gap in how devices are design.
This project will close that gap by studying blood trauma in both lab models and real patients. In the lab, blood will circulate through clinical-grade artificial hearts (n=10) and tested for changes in cell health, platelet activation (how easily they trigger clotting) and inflammation. In parallel, ~12 patients receiving an artificial heart will also be studied. Blood will be collected before surgery, immediately after, and at 1, 3, 6, and 12 months using the same advanced tests.
By combining advanced lab experiments with real patient testing, this project will give the most complete picture of blood trauma to date. These insights will help engineers refine devices to limit blood injury. Patient testing will also determine how these blood injuries can be tracked as biomarkers to monitor device safety and related complications.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Queensland, Australia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
537746
Name
Steele Andrew R
Region
Queensland
Country
Australia
Orgtype
Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Hemocompatibility and red blood cell trauma in next-generation total artificial hearts
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Biophysics; Blood Damage; Heart Failure; Inflammation; Mechanical Support Devices; Mechanobiology; Microfluidics; Total Artificial Hearts
Abstract
Heart failure affects more than 750,000 Canadians, with 100,000 new diagnoses each year, costing the health care system $19.5B. For people with severe, end-stage disease, a heart transplant is the best option, but ~15% die while waiting. To fill this gap, mechanical circulatory support devices, such as left ventricular assist devices and total artificial hearts, are used to keep patients alive while waiting for a transplant or as long-term therapy. These devices improve short-term survival but are limited by complications like blood clots, stroke, bleeding and organ failure. Nearly all patients develop clotting problems, causing repeat hospitalizations.
A major reason for these complications is "blood trauma." As blood moves through pumps made of artificial materials, red blood cells (RBCs) are exposed to unnatural stresses and surfaces. Even if RBCs do not burst, they can become stiff, inflamed or break down too quickly, which harms circulation and causes clots, bleeding and poor blood flow. Current safety standards only test for cell rupture (called hemolysis) and miss this subtler damage, leaving a critical gap in how devices are design.
This project will close that gap by studying blood trauma in both lab models and real patients. In the lab, blood will circulate through clinical-grade artificial hearts (n=10) and tested for changes in cell health, platelet activation (how easily they trigger clotting) and inflammation. In parallel, ~12 patients receiving an artificial heart will also be studied. Blood will be collected before surgery, immediately after, and at 1, 3, 6, and 12 months using the same advanced tests.
By combining advanced lab experiments with real patient testing, this project will give the most complete picture of blood trauma to date. These insights will help engineers refine devices to limit blood injury. Patient testing will also determine how these blood injuries can be tracked as biomarkers to monitor device safety and related complications.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Steele, Andrew R
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~